









































Methotrexate-induced Acute Myelopathy in a Teenager
With High-risk Acute Lymphoblastic Leukemia
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Summary: Acute lymphoblastic leukemia (ALL) is one of the most
frequent malignancies in childhood whose long-term survival has
increased up to 80% thanks to modern therapy enhancements. Nev-
ertheless, methotrexate (MTX) remains a mainstay of ALL therapy,
but also represents one of the major causes of neurotoxicity in patients
with ALL. MTX-induced toxicity occurs in about 9% of patients
treated for ALL. It usually affects deep white matter region leading to
leukoencephalopathy, which has varying clinical manifestations
ranging from acute neurological disturbances to seizures or chronic
permanent encephalopathy. Here we describe a 13-year-old girl
affected with ALL who developed lower limbs hypesthesia and static
ataxia due to transverse myelopathy after intrathecal administration
of MTX therapy. A high-dose corticotherapy combined to vitamin
supplementation and rehabilitation was tested. Neurological evolution
was characterized by slow and partial recovery.
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A cute lymphoblastic leukemia (ALL) is one of the mostcommon childhood malignancies. Methotrexate (MTX)
is an essential drug in the treatment of ALL. It can be
administrated intravenously (IV) or via intrathecal (IT)
route and is able to cross the brain-blood barrier to erad-
icate leukemic cells from central nervous system (CNS).
High doses (HD) of IV MTX prevent not only CNS leu-
kemic invasion but also systemic relapses.
MTX is known to generate neurotoxic side effects, that
have been classified as either acute/subacute or chronic ence-
phalopathy. The reported incidence of MTX-related neuro-
toxicity for patients with ALL is between 9% and 53%.1
Acute encephalopathy is a transient complication occur-
ring generally within 5 to 14 days after IT MTX or HD IV
MTX: it may include headache, altered mental status, impaired
vision, seizure, and sometimes focal deficits. Hypertension is
usually present. This encephalopathy is known as “posterior
reversible encephalopathy syndrome” (PRES).2 The mecha-
nisms underlying the pathogenesis of this syndrome are not
fully understood; PRES is characterized by white matter edema
in the occipital-parietal lobes, which are brain areas supplied by
the posterior circulation. It usually resolves within a week
without permanent neurological sequelae. A “stroke-like syn-
drome” (SLS)—a subacute MTX-related neurotoxicity—is also
well described as methotrexate neurological complication; the
clinical features typically include focal weakness or hemiparesis,
often accompanied by disturbances in speech and/or affect,
which may wax and wane over the course of hours to days.
Magnetic resonance imaging (MRI) may rule out a vascular
stroke and show consistent cerebral white matter changes.2,3
SLS is completely reversible without stroke treatment
protocol.4 The pathogenesis of SLS toxicity remains poorly
understood but seems to be correlated with IT MTX. While
these acute syndromes are transient, chronic MTX neuro-
toxicity may manifest either as neurocognitive dysfunction or as
diffuse progressive leukoencephalopathy. The latter develops
more slowly, progress, evolving sometimes into dementia with
permanent neurological deficits and seizures. It occurs usually
in case of concomitant radiation, and settles several months
after the beginning of treatment.1,5 Cases of asymptomatic
MTX-induced white matter lesions on MRI have also been
observed.
The risk factors for MTX-related neurotoxicity include
age younger than 10,1 HD, IT route, association with other
chemotherapeutic drugs (cyclophosphamide and aracytine)
and concomitant cranial irradiation.5–7
Here, we report the case of a 13-year-old girl who
developed transverse myelitis after MTX therapy for ALL.
CASE DESCRIPTION
Y.T., a 13-year-old Turkish girl was diagnosed with B-cell
ALL. Owing to an IKAROS deletion and the occurrence of lym-
phoblastic meningitis on day 12 of therapy, she was treated in the
very high risk group of EORTC 58081 protocol.
She developed several treatment-related toxicities: corticosteroid-
induced insulin-dependent diabetes, cholestatic jaundice, and major
hypertriglyceridemia following asparaginase therapy. She also suffered
from pulmonary aspergillosis and severe corticosteroid-induced osteo-
necrosis in both knees.
After 7 months of intensive chemotherapy, the patient began
to experience numbness in feet with slight ataxia and symmetric
distal hypoesthesia in lower limbs. Electromyographic study showed
a reduction in sensory and motor nerve conduction velocity, and a
decrease in motor response amplitude. Distal motor latencies were
prolonged, which was compatible with both axonal and demyeli-
nating polyneuropathy. That neuropathy was first attributed to
vincristine, and vitamin B supplementation was prescribed but
without clinical benefit. Gradually, the numbness become more
marked and hypoesthesia of lower limbs ascended to perineum and
lower abdomen. The patient experienced loss of sensitivity during
miction and defecation with occasional urinary and fecal incon-
tinence. Clinical examination revealed a sensory level around
T10, paraparesis with areflexia and static and kinetic ataxia
impairing walk.
The MRI in short TI inversion recovery ponderation showed
homogenous hyperintensity in posterior segment from T9 to T11,
without gadolinium enhancement, suggesting a dorsal myelitis
(Fig. 1). Differential diagnosis included postinfectious acute myel-
opathy, or toxic transverse myelitis.
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A lumbar puncture revealed a slight elevation in cerebrospinal
fluid (CSF) protein without lymphoblastic invasion. Polymerase
chain reaction for JC/BK virus, Mycoplasma, and Herpes simplex
virus infection in CSF were negative. CSF Methionine level was
low, highlighting blood-brain barrier integrity.
IT MTX and cytosine arabinoside (Ara-C) injections were
suspended and CNS prophylaxis was achieved through methyl-
prednisolone IT injections alone. Further scheduled doses of HD IV
MTX were also cancelled. Three courses of HD methylprednisone
(1 g/m2/d for 3 consecutive days) were followed by transient clinical
improvement.
Because of persistent symptoms Dextromethorphan (1mg/kg/d),
was initiated as recommended by Drachtman et al8 associated with 4
courses of HD vitamin (S-adenosylmethionine 200mg 3 times daily
IV, folinate 20mg 4 times daily IV, cyanocobalamin 100mcg once
daily IV, and methionine 5 g daily PO) for 5 consecutive days as
proposed by Ackermann et al.9 Mobilization and revalidation were
complicated to start due to relative discharge required by bone
necrosis in the knees.
Evolution of neurological symptomatology was slowly
favorable with progressive partial recuperation. After 9 months,
there was persistance of attenuated kinetic ataxia and distal num-
bess in lower extremities. Evoked potential revealed a slight increase
in responses, whereas medullary MRI showed total regression of
signal abnomality in 6 months. One year later, the patient is still in
first complete ALL remission.
DISCUSSION
Our patient developed toxic transverse myelopathy
during antileukemic therapy. She first developed numbness
in feet with symmetric distal hypoesthesia in lower limbs
and abnormal somaesthetic evoked potential (EP) suggest-
ing peripheral neuropathy due to axonal impairment.
Nevetherless, progressive normalization of EP suggests a
medullary injury, which was confirmed by MRI.
Biological parameters and paraclinic results suggest in
our case a toxic etiology. Before appearance of first clinical
myelitis symptoms, Y.T. received at all 4 courses of HD IV
MTX (5 g/sqm/course) and 16 IT chemotherapy (MTX,
cytosine arabinoside, and solumedrol). Our patient received
leucovorin rescue as recommended after HD MTX; MTX
levels have been systematically measured at 48, 60, 72, and
96 hours after the start of each course of MTX infusion and
were always in the normal range. The neurological symp-
toms appeared 3 months after the last course of HD IV
MTX but 10 days after the last IT therapy.
That temporal relationship between MTX admin-
istration and neurological symptomatology suggests that
toxic myelopathy may be linked to IT chemotherapy more
than IV methotrexate.
Even if MTX-neurotoxicity is the most common drug
induced neurotoxicity in ALL patients, IT cytosine
arabinoside,10 and thiotepa11 have also been incriminated.
Total doses of chemotherapy received by our patient before
the occurence of myelitis are described in Table 1.
Methotrexate-induced acute myelopathy is a rare and
debilitating complication of intrathecal therapy, a few cases
have been described in the literature.12–14
FIGURE 1. Resonance magnetic imaging. A, T2-weighted sequence, sagittal view at diagnosis showing hyperintensity in dorsal (T9 and T10)
posterior medullary columns. B, *T2 sequence, axial view. C, Medullary magnetic resonance imaging at 6 weeks, showing attenuation of
previous defects. *indicates arrows.
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It usually presents with back pain, ascending lower
limbs hypoesthesia evolving to paraparesis and sphincter
dysfunction—as described in our patient. According to
reports, ∼3% of patients treated with IT MTX or Ara-C
would develop such toxicity within hours or days after
injections.12 This has also been described after intra-
muscular MTX injections.15
Patients with preexisting CNS involvement or exposed
to concomitant N2O sedation, CNS radiation or IV MTX
are at higher risk of developing such a complication.16
Several genetic polymorphisms implicated in neurogenesis
have been hypothesized to confer susceptibility to MTX
neurotoxicity (TRIO, PRKG1, ANK1, COL4A2, etc.),17
but were not studied in our patient.
In the literature, the occurence of myelitis appears to be
independent of delayed intravenous MTX excretion and
plasmatic MTX concentration.1 The use of folinic acid res-
cue does not seem to alleviate neurological symptomatology.
As opposed to MTX-induced subacute encephalopathy
which evolves favorably in a few days and does not recur
when the drug is readministrered to the patient,17 neuro-
logical recover following myelitis is longer and often exac-
erbates following further MTX injections.13
Myelitis management includes interruption of toxic drugs
and early rehabilitation. Potential pharmaceutical therapeutic
options are as follow: (1) dextromethorphan, (2) HD cortico-
steroid, (3) HD vitamins supplementation. The 2 last options
have led to spectacular ameliorations in the literature,9 whereas
the positive impact of HD steroid, more frequently described, is
sometimes mitigated. Dextromethorphan, a noncompetitive
N-methyl-D-aspartate (NMDA) receptor antagonist, has been
shown to alleviated neurological complaints within 24 hours for
patients experiencing subacute MTX-induced encephalopathy.8
This effect may be due to the fact that NMDA receptor, a
glutamate receptor and ion channel protein, is highly expressed
in nerve cells. However, dextromethorphan has not been tested
in patients with MTX-induced myelitis or tested in randomized-
controlled trials. Its efficacy in acute neurotoxicity has also been
questioned, as cases of spontaneous favorable evolution have
also been described.
CONCLUSIONS
Transverse myelopathy is a rare but serious subacute
complication of MTX-based chemotherapy. It does not appear
to be linked to plasmatic concentrations or to delayed excre-
tion, but IT route of MTX administration seems to promote its
occurence. Genetic predisposition has also been hypothesized.
Recovery is slow and more often incomplete. It requires
definitive MTX interruption, early rehabilitation and may be
boosted by drug therapy such as NDMA receptor antago-
nist, vitamin supplementation, and corticosteroid.
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